Clinical Focus ›› 2021, Vol. 36 ›› Issue (8): 724-729.doi: 10.3969/j.issn.1004-583X.2021.08.010
Previous Articles Next Articles
Peng Zhenli(), Jiang Yao, Jia Lijuan, Wang Yanxin, Xue Weixiao, Shi Huiting
Received:
2021-07-15
Online:
2021-08-20
Published:
2021-08-30
Contact:
Peng Zhenli
E-mail:pengzhenli@163.com
CLC Number:
Peng Zhenli, Jiang Yao, Jia Lijuan, Wang Yanxin, Xue Weixiao, Shi Huiting. Analysis of pathogenic bacteria resistance and prognosis of bloodstream infection[J]. Clinical Focus, 2021, 36(8): 724-729.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.08.010
抗菌药物 | MRSA(n=9) | MSSA(n=1) | MRCNS(n=36) | MSCNS(n=4) | ||||
---|---|---|---|---|---|---|---|---|
耐药率 | 敏感率 | 耐药率 | 敏感率 | 耐药率 | 敏感率 | 耐药率 | 敏感率 | |
万古霉素 | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 |
替考拉宁 | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 |
利奈唑胺 | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 |
利福平 | 44.44 | 55.56 | 0 | 100 | 11.11 | 88.89 | 0 | 100 |
环丙沙星 | 22.22 | 77.78 | 0 | 100 | 80.56 | 19.44 | 25.00 | 75.00 |
庆大霉素 | 12.50 | 7.78 | 50.00 | 50.00 | 20.00 | 80.00 | 75.00 | 25.00 |
甲氧苄啶-磺胺甲噁唑 | 0 | 100 | 0 | 100 | 33.33 | 66.667 | 75.00 | 25.00 |
红霉素 | 11.11 | 88.89 | 100 | 0 | 100 | 0 | 75.00 | 25.00 |
克林霉素 | 66.67 | 33.33 | 0 | 100 | 30.56 | 69.44 | 25.00 | 75.00 |
四环素 | 77.78 | 22.22 | 0 | 100 | 83.33 | 91.67 | 25.00 | 75.00 |
青霉素G | 100 | 0 | 100 | 0 | 100 | 0 | 100 | 0 |
苯唑西林 | 100 | 0 | 0 | 100 | 100 | 0 | 75.00 | 25.00 |
抗菌药物 | MRSA(n=9) | MSSA(n=1) | MRCNS(n=36) | MSCNS(n=4) | ||||
---|---|---|---|---|---|---|---|---|
耐药率 | 敏感率 | 耐药率 | 敏感率 | 耐药率 | 敏感率 | 耐药率 | 敏感率 | |
万古霉素 | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 |
替考拉宁 | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 |
利奈唑胺 | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 |
利福平 | 44.44 | 55.56 | 0 | 100 | 11.11 | 88.89 | 0 | 100 |
环丙沙星 | 22.22 | 77.78 | 0 | 100 | 80.56 | 19.44 | 25.00 | 75.00 |
庆大霉素 | 12.50 | 7.78 | 50.00 | 50.00 | 20.00 | 80.00 | 75.00 | 25.00 |
甲氧苄啶-磺胺甲噁唑 | 0 | 100 | 0 | 100 | 33.33 | 66.667 | 75.00 | 25.00 |
红霉素 | 11.11 | 88.89 | 100 | 0 | 100 | 0 | 75.00 | 25.00 |
克林霉素 | 66.67 | 33.33 | 0 | 100 | 30.56 | 69.44 | 25.00 | 75.00 |
四环素 | 77.78 | 22.22 | 0 | 100 | 83.33 | 91.67 | 25.00 | 75.00 |
青霉素G | 100 | 0 | 100 | 0 | 100 | 0 | 100 | 0 |
苯唑西林 | 100 | 0 | 0 | 100 | 100 | 0 | 75.00 | 25.00 |
抗菌药物 | 大肠埃希菌 | 肺炎克雷伯菌 | 阴沟肠杆菌(n=2) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
ESBLS(+)(n=5) | ESBLS(-)(n=4) | ESBLS(+)(n=5) | ESBLS(-)(n=1) | 耐药率 | 敏感率 | |||||
耐药率 | 敏感率 | 耐药率 | 敏感率 | 耐药率 | 敏感率 | 耐药率 | 敏感率 | |||
阿米卡星 | 0 | 100 | 0 | 100 | 20.00 | 80.00 | 0 | 100 | 0 | 100 |
庆大霉素 | 20.00 | 80.00 | 50.00 | 50.00 | 60.00 | 40.00 | 0 | 100 | 0 | 100 |
阿莫西林-克拉维酸 | 40.00 | 60.00 | 50.00 | 50.00 | 100 | 0 | 0 | 100 | 100 | 0 |
氨苄西林-舒巴坦 | 20.00 | 80.00 | 50.00 | 50.00 | 100 | 0 | 0 | 100 | 100 | 0 |
哌拉西林 | 100 | 0 | 25.00 | 75.00 | 100 | 0 | 0 | 100 | 100 | 0 |
哌拉西林-他唑巴坦 | 0 | 100 | 0 | 100 | 20.00 | 80.00 | 0 | 100 | 100 | 0 |
头孢唑林 | 100 | 0 | 50.00 | 50.00 | 100 | 0 | 0 | 100 | 100 | 0 |
头孢他啶 | 20.00 | 80.00 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 100 |
头孢噻肟 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 100 |
头孢吡肟 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 100 |
氨曲南 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 100 |
亚胺培南 | 0 | 100 | 0 | 100 | 40.00 | 60.00 | 0 | 100 | 0 | 100 |
美罗培南 | 0 | 100 | 0 | 100 | 40 | 60 | 0 | 100 | 0 | 100 |
环丙沙星 | 80.00 | 20.00 | 0 | 100 | 80.00 | 20.00 | 0 | 100 | 0 | 100 |
左氧氟沙星 | 60.00 | 40.00 | 0 | 100 | 60.00 | 40.00 | 0 | 100 | 0 | 100 |
莫西沙星 | 80.00 | 20.00 | 25.00 | 75.00 | 80.00 | 20.00 | 25.00 | 75.00 | 0 | 100 |
甲氧苄啶-磺胺甲噁唑 | 60.00 | 40.00 | 50.00 | 50.00 | 60.00 | 40.00 | 50.00 | 50.00 | 0 | 100 |
四环素 | 80.00 | 20.00 | 75.00 | 25.00 | 100 | 0 | 75.00 | 25.00 | 0 | 100 |
多黏菌素B | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 |
氯霉素 | 60.00 | 40.00 | 0 | 100 | 60.00 | 40.00 | 0 | 100 | 0 | 100 |
抗菌药物 | 大肠埃希菌 | 肺炎克雷伯菌 | 阴沟肠杆菌(n=2) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
ESBLS(+)(n=5) | ESBLS(-)(n=4) | ESBLS(+)(n=5) | ESBLS(-)(n=1) | 耐药率 | 敏感率 | |||||
耐药率 | 敏感率 | 耐药率 | 敏感率 | 耐药率 | 敏感率 | 耐药率 | 敏感率 | |||
阿米卡星 | 0 | 100 | 0 | 100 | 20.00 | 80.00 | 0 | 100 | 0 | 100 |
庆大霉素 | 20.00 | 80.00 | 50.00 | 50.00 | 60.00 | 40.00 | 0 | 100 | 0 | 100 |
阿莫西林-克拉维酸 | 40.00 | 60.00 | 50.00 | 50.00 | 100 | 0 | 0 | 100 | 100 | 0 |
氨苄西林-舒巴坦 | 20.00 | 80.00 | 50.00 | 50.00 | 100 | 0 | 0 | 100 | 100 | 0 |
哌拉西林 | 100 | 0 | 25.00 | 75.00 | 100 | 0 | 0 | 100 | 100 | 0 |
哌拉西林-他唑巴坦 | 0 | 100 | 0 | 100 | 20.00 | 80.00 | 0 | 100 | 100 | 0 |
头孢唑林 | 100 | 0 | 50.00 | 50.00 | 100 | 0 | 0 | 100 | 100 | 0 |
头孢他啶 | 20.00 | 80.00 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 100 |
头孢噻肟 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 100 |
头孢吡肟 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 100 |
氨曲南 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 100 |
亚胺培南 | 0 | 100 | 0 | 100 | 40.00 | 60.00 | 0 | 100 | 0 | 100 |
美罗培南 | 0 | 100 | 0 | 100 | 40 | 60 | 0 | 100 | 0 | 100 |
环丙沙星 | 80.00 | 20.00 | 0 | 100 | 80.00 | 20.00 | 0 | 100 | 0 | 100 |
左氧氟沙星 | 60.00 | 40.00 | 0 | 100 | 60.00 | 40.00 | 0 | 100 | 0 | 100 |
莫西沙星 | 80.00 | 20.00 | 25.00 | 75.00 | 80.00 | 20.00 | 25.00 | 75.00 | 0 | 100 |
甲氧苄啶-磺胺甲噁唑 | 60.00 | 40.00 | 50.00 | 50.00 | 60.00 | 40.00 | 50.00 | 50.00 | 0 | 100 |
四环素 | 80.00 | 20.00 | 75.00 | 25.00 | 100 | 0 | 75.00 | 25.00 | 0 | 100 |
多黏菌素B | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 | 0 | 100 |
氯霉素 | 60.00 | 40.00 | 0 | 100 | 60.00 | 40.00 | 0 | 100 | 0 | 100 |
抗菌药物 | 不动杆菌属(n=6) | 铜绿假单胞菌(n=3) | ||
---|---|---|---|---|
耐药率 | 敏感率 | 耐药率 | 敏感率 | |
阿米卡星 | 33.33 | 66.67 | 0 | 100 |
庆大霉素 | 33.33 | 66.67 | 0 | 100 |
哌拉西林 | 33.33 | 66.67 | 0 | 100 |
哌拉西林-他唑巴坦 | 33.33 | 66.67 | 0 | 100 |
氨苄西林-舒巴坦 | 33.33 | 66.67 | 100 | 0 |
头孢噻肟 | 33.33 | 66.67 | 100 | 0 |
头孢他啶 | 50.00 | 50.00 | 0 | 100 |
头孢吡肟 | 33.33 | 66.67 | 33.33 | 66.67 |
氨曲南 | 100 | 0 | 33.33 | 66.67 |
亚胺培南 | 33.33 | 66.67 | 0 | 100 |
美罗培南 | 33.33 | 66.67 | 0 | 100 |
环丙沙星 | 50.00 | 50.00 | 0 | 100 |
左氧氟沙星 | 50.00 | 50.00 | 33.33 | 66.67 |
甲氧苄啶-磺胺甲噁唑 | 0 | 100 | 100 | 0 |
多黏菌素B | 0 | 100 | 0 | 100 |
抗菌药物 | 不动杆菌属(n=6) | 铜绿假单胞菌(n=3) | ||
---|---|---|---|---|
耐药率 | 敏感率 | 耐药率 | 敏感率 | |
阿米卡星 | 33.33 | 66.67 | 0 | 100 |
庆大霉素 | 33.33 | 66.67 | 0 | 100 |
哌拉西林 | 33.33 | 66.67 | 0 | 100 |
哌拉西林-他唑巴坦 | 33.33 | 66.67 | 0 | 100 |
氨苄西林-舒巴坦 | 33.33 | 66.67 | 100 | 0 |
头孢噻肟 | 33.33 | 66.67 | 100 | 0 |
头孢他啶 | 50.00 | 50.00 | 0 | 100 |
头孢吡肟 | 33.33 | 66.67 | 33.33 | 66.67 |
氨曲南 | 100 | 0 | 33.33 | 66.67 |
亚胺培南 | 33.33 | 66.67 | 0 | 100 |
美罗培南 | 33.33 | 66.67 | 0 | 100 |
环丙沙星 | 50.00 | 50.00 | 0 | 100 |
左氧氟沙星 | 50.00 | 50.00 | 33.33 | 66.67 |
甲氧苄啶-磺胺甲噁唑 | 0 | 100 | 100 | 0 |
多黏菌素B | 0 | 100 | 0 | 100 |
指标 | 转归 | Z/t/χ2值 | P值 | |
---|---|---|---|---|
好转 | 死亡 | |||
性别[例(%)] | ||||
男 女 | 21(39.6) 32(60.4) | 12(44.4) 15(55.6) | 0.172 | 0.679 |
年龄(岁) | 71.79±15.92 | 77.93±11.04 | -1.791 | 0.077 |
是否医院获得性感染[例(%)] | ||||
否 是 | 13(24.5) 40(75.5) | 8(29.6) 19(70.4) | 0.240 | 0.624 |
院感发生于入ICU前[例(%)] | ||||
否 是 | 48(90.6) 5(9.4) | 23(85.2) 4(14.8) | 0.120 | 0.729 |
院感发生于入ICU后[例(%)] | ||||
否 是 | 18(34.0) 35(66.0) | 12(44.4) 15(55.6) | 0.839 | 0.360 |
感染部位[例(%)] | ||||
导管相关性血行感染 | 21(39.6) | 12(44.4) | ||
实体器官感染 | 17(32.1) | 5(18.5) | 3.760 | 0.289 |
手术或操作相关 | 5(9.4) | 1(3.7) | ||
原发菌血症 | 10(18.9) | 9(33.3) | ||
基础疾病[例(%)] | ||||
无 | 9(17.0) | 6(22.2) | ||
恶性肿瘤 | 2(3.8) | 2(7.4) | 1.526 | 0.679 |
糖尿病 | 19(35.8) | 7(25.9) | ||
其他 | 23(43.4) | 12(44.4) | ||
机械通气>72 h[例(%)] | ||||
否 是 | 21(39.6) 32(60.4) | 8(29.6) 19(70.4) | 0.773 | 0.379 |
留置血管导管[例(%)] | ||||
否 是 | 20(37.7) 33(62.3) | 6(22.2) 21(77.8) | 1.962 | 0.161 |
血液净化治疗[例(%)] | ||||
否 是 | 42(79.2) 11(20.8) | 21(77.8) 6(22.2) | 0.023 | 0.879 |
手术[例(%)] | ||||
否 是 | 32(60.4) 21(39.6) | 22(81.5) 5(18.5) | 3.632 | 0.057 |
同时生长两种菌[例(%)] | ||||
否 是 | 53(100.0) 0 | 23(85.2) 4(14.8) | 5.440 | 0.020 |
住ICU总天数(d) | 17.00(7.00, 30.00) | 15.00(7.00, 24.00) | -0.728 | 0.467 |
住院天数(d) | 30.00(17.50, 50.50) | 22.00(12.00, 35.00) | -1.842 | 0.065 |
血流感染发生时间(h) | 4.00(0.50, 12.00) | 3.00(0.00, 10.00) | -1.179 | 0.239 |
血培养阳性报警时间(h) | 21.39(15.08, 26.50) | 20.33(14.33, 30.50) | -0.122 | 0.903 |
血培养报警瓶数(瓶) | 1.00(1.00, 2.00) | 2.00(1.00, 3.00) | -1.803 | 0.071 |
指标 | 转归 | Z/t/χ2值 | P值 | |
---|---|---|---|---|
好转 | 死亡 | |||
性别[例(%)] | ||||
男 女 | 21(39.6) 32(60.4) | 12(44.4) 15(55.6) | 0.172 | 0.679 |
年龄(岁) | 71.79±15.92 | 77.93±11.04 | -1.791 | 0.077 |
是否医院获得性感染[例(%)] | ||||
否 是 | 13(24.5) 40(75.5) | 8(29.6) 19(70.4) | 0.240 | 0.624 |
院感发生于入ICU前[例(%)] | ||||
否 是 | 48(90.6) 5(9.4) | 23(85.2) 4(14.8) | 0.120 | 0.729 |
院感发生于入ICU后[例(%)] | ||||
否 是 | 18(34.0) 35(66.0) | 12(44.4) 15(55.6) | 0.839 | 0.360 |
感染部位[例(%)] | ||||
导管相关性血行感染 | 21(39.6) | 12(44.4) | ||
实体器官感染 | 17(32.1) | 5(18.5) | 3.760 | 0.289 |
手术或操作相关 | 5(9.4) | 1(3.7) | ||
原发菌血症 | 10(18.9) | 9(33.3) | ||
基础疾病[例(%)] | ||||
无 | 9(17.0) | 6(22.2) | ||
恶性肿瘤 | 2(3.8) | 2(7.4) | 1.526 | 0.679 |
糖尿病 | 19(35.8) | 7(25.9) | ||
其他 | 23(43.4) | 12(44.4) | ||
机械通气>72 h[例(%)] | ||||
否 是 | 21(39.6) 32(60.4) | 8(29.6) 19(70.4) | 0.773 | 0.379 |
留置血管导管[例(%)] | ||||
否 是 | 20(37.7) 33(62.3) | 6(22.2) 21(77.8) | 1.962 | 0.161 |
血液净化治疗[例(%)] | ||||
否 是 | 42(79.2) 11(20.8) | 21(77.8) 6(22.2) | 0.023 | 0.879 |
手术[例(%)] | ||||
否 是 | 32(60.4) 21(39.6) | 22(81.5) 5(18.5) | 3.632 | 0.057 |
同时生长两种菌[例(%)] | ||||
否 是 | 53(100.0) 0 | 23(85.2) 4(14.8) | 5.440 | 0.020 |
住ICU总天数(d) | 17.00(7.00, 30.00) | 15.00(7.00, 24.00) | -0.728 | 0.467 |
住院天数(d) | 30.00(17.50, 50.50) | 22.00(12.00, 35.00) | -1.842 | 0.065 |
血流感染发生时间(h) | 4.00(0.50, 12.00) | 3.00(0.00, 10.00) | -1.179 | 0.239 |
血培养阳性报警时间(h) | 21.39(15.08, 26.50) | 20.33(14.33, 30.50) | -0.122 | 0.903 |
血培养报警瓶数(瓶) | 1.00(1.00, 2.00) | 2.00(1.00, 3.00) | -1.803 | 0.071 |
指标 | 回归系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
同时生长两种菌 | 2.225 | 1.148 | 3.757 | 0.053 | 9.249 | 0.976 | 87.686 |
血培养阳性报警时间(h) | 0.015 | 0.014 | 1.025 | 0.311 | 1.015 | 0.986 | 1.044 |
指标 | 回归系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
同时生长两种菌 | 2.225 | 1.148 | 3.757 | 0.053 | 9.249 | 0.976 | 87.686 |
血培养阳性报警时间(h) | 0.015 | 0.014 | 1.025 | 0.311 | 1.015 | 0.986 | 1.044 |
[1] | 赵志刚, 邱添, 梁志欣, 等. 医院获得性铜绿假单胞菌血流感染临床特征及死亡危险因素分析[J]. 解放军医学院学报, 2016, 37(4):324-327. |
[2] |
Zhu S, Kang Y, Wang W, et al. The clinical impacts and risk factors for non-central line-associated bloodstream infection in 5046 intensive care unit patients: An observational study based on electronic medical records[J]. Crit Care, 2019, 23(1):52.
doi: 10.1186/s13054-019-2353-5 URL |
[3] |
Xie J, Li S, Xue M, et al. Early- and late-onset bloodstream infections in the intensive care unit: A retrospective 5-year study of patients at a university hospital in China[J]. J Infect Dis, 2020, 221(Suppl 2):S184-184S192.
doi: 10.1093/infdis/jiz606 URL |
[4] | 中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志, 2001, 81(5):314-320. |
[5] | 黄勋, 邓子德, 倪语星, 等. 多重耐药菌医院感染预防与控制中国专家共识[J]. 中国感染控制杂志, 2015, 14(1):1-9. |
[6] | 尚红, 王毓三, 申子瑜, 等. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社, 2015:560-811. |
[7] | 王敏, 许顺姬, 金春梅, 等. 血培养阳性报警时间对临床病原菌鉴别的探讨[J]. 中华医院感染学杂志, 2017, 27(3):528-531. |
[8] | 许健波, 朱以军, 单小云. 菌血症患者的病原菌分布及血培养阳性报警时间分析[J]. 中华医院感染学杂志, 2012, 22(11):2469-2471. |
[9] |
Tang PC, Lee CC, Li CW, et al. Time-to-positivity of blood culture: An independent prognostic factor of monomicrobial Pseudomonas aeruginosa bacteremia[J]. J Microbiol Immunol Infect, 2017, 50(4):486-493.
doi: 10.1016/j.jmii.2015.08.014 URL |
[10] | 刘乐平, 刘文恩, 晏群, 等. 2012-2015年某三甲医院血培养常见病原菌及其耐药性变迁[J]. 中国感染控制杂志, 2016, 15(6):374-379. |
[11] |
Pien BC, Sundaram P, Raoof N, et al. The clinical and prognostic importance of positive blood cultures in adults[J]. Am J Med, 2010, 123(9):819-828.
doi: 10.1016/j.amjmed.2010.03.021 URL |
[12] | 杨小平, 许小敏, 陈琳, 等. 血流感染患者病原菌特点与死亡相关因素分析[J]. 中华医院感染学杂志, 2018, 28(8):1154-1157. |
[13] | 胡田雨, 陈雪娥, 金浩龙, 等. 某三甲综合医院医院获得性血流感染病原菌分布及耐药性分析[J]. 中华医院感染学杂志, 2018, 28(8):1139-1143, 1178. |
[14] | 吕媛, 李耘, 薛峰, 等. 卫生部全国细菌耐药监测网(Mohnarin)2011-2012年度血流感染细菌耐药监测报告[J]. 中国临床药理学杂志, 2014, 30(3):278-288. |
[15] | 黄匀, 龚晨晨, 付建宇, 等. 重症监护病房血流感染预后危险因素分析[J]. 中华危重病急救医学, 2020, 32(12):1440-1444. |
[16] | 周梦兰, 杨启文, 于淑颖, 等. 血流感染流行病学研究进展[J]. 中国感染与化疗杂志, 2019, 19(2):212-217. |
[17] |
May L, Klein EY, Rothman RE, et al. Trends in antibiotic resistance in coagulase-negative staphylococci in the United States, 1999 to 2012[J]. Antimicrob Agents Chemother, 2014, 58(3):1404-1409.
doi: 10.1128/AAC.01908-13 URL |
[18] | 胡丹辰, 孙争辉, 孙建斌, 等. 凝固酶阴性葡萄球菌感染患者临床特征及万古霉素药效学分析[J]. 中华医院感染学杂志, 2020, 30(1):20-24. |
[19] | Matarrese AN, Ivulich DI, Cesar G, et al. Epidemiological analysis of catheter-related bloodstream infections in medical-surgical intensive care units[J]. Medicina (B Aires), 2021, 81(2):159-165. |
[20] | 胡洪华, 杨永长, 肖代雯, 等. 凝固酶阴性葡萄球菌生物被膜形成及耐药性分析[J]. 中国感染控制杂志, 2015, 14(11):721-725. |
[21] | 刘军. 耐甲氧西林金黄色葡萄球菌血流感染:关注感染来源和去路[J]. 中华重症医学电子杂志:网络版, 2019, 5(2):109-114. |
[22] |
Dat VQ, Long NT, Hieu VN, et al. Clinical characteristics, organ failure, inflammatory markers and prediction of mortality in patients with community acquired bloodstream infection[J]. BMC Infect Dis, 2018, 18(1):535.
doi: 10.1186/s12879-018-3448-3 URL |
[23] | 逯峰, 马德晶, 朱委委, 等. 肠杆菌科细菌致血流感染重症患者的预后分析[J]. 中华危重病急救医学, 2020, 32(4):454-457. |
[24] | 刘刚, 魏莲花, 邹凤梅, 等. 2011~2016年耐碳青霉烯类抗菌药物肠杆菌科细菌的分布特点和耐药性分析[J]. 中国医药科学, 2018, 8(9):20-23. |
[25] | 邓医宇, 申凤彩, 林琼瑜, 等. 重症监护病房内血流感染危险因素及预后分析[J]. 中华急诊医学杂志, 2015, 24(12):1425-1429. |
[26] |
Rogne T, Solligård E, Burgess S, et al. Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study[J]. PLoS Med, 2020, 17(11):e1003413.
doi: 10.1371/journal.pmed.1003413 URL |
[1] | Huang Saihu, Long Zhongjie, Dong Xingqiang, Meng Xiangying, Wu Shuiyan, Bai Zhenjiang. Pathogen and clinical characteristics of children with hematologic neoplasms complicated with sepsis [J]. Clinical Focus, 2024, 39(1): 38-42. |
[2] | Guo Hao, Zhuang Huicui, Yang Limei, Ren Jing, Cui Dongsheng, Zhang Liran. 2019-2021 pathogen infection characteristics and drug resistance analysis on patients from Intensive Care Unit of the Hospital [J]. Clinical Focus, 2022, 37(6): 519-524. |
[3] | Zhu Ying, Shu Qianqian, Chen Fuhui. Clinical characteristics and drug resistance of community-acquired Acinetobacter baumannii pneumonia [J]. Clinical Focus, 2022, 37(4): 315-319. |
[4] | Li Shufan, Wang Yuxiu, Jiang Zhenghua. The correlation between the prognosis of lung adenocarcinoma with acquired resistance to the first-generation EGFR TKI and the T790M mutation [J]. Clinical Focus, 2022, 37(11): 985-991. |
[5] | Hou Wei, Zhang Lijun, Zhang Man, Wang Yakun, Jia Meixuan, Tian Liyuan. Clinical analysis in 84 children with the sepsis of non-elevated peripheral blood leukocytes [J]. Clinical Focus, 2021, 36(9): 799-802. |
[6] | Cai Mujing, Chen Jingjing, Huang Rukun, Cai Xiaoni, Zheng Ruoxian. Epidemiological characteristics, underlying diseases and treatments of elderly hospitalized patients with pneumonia [J]. Clinical Focus, 2021, 36(3): 229-232. |
[7] | Shen Ziyuan, Kang Haiquan, Sang Wei, Yan Dongmei. Analysis of bacterial distribution, resistance and risk factor of death of bacterial infection in leukemia patients [J]. Clinical Focus, 2021, 36(12): 1092-1096. |
[8] | Li Xiaa, Ma Gaoxib, Hu Linglingc,Dong Fengmeib. Distribution and drug resistance of Streptococcus pneumoniae infection in children [J]. Clinical Focus, 2020, 35(2): 170-173. |
[9] | Yin Haiqing1a, Yao Baoguo2a, Chen Wanzhen1b, Su Li2b. Risk factors and drug resistance of Carbapenemresistant Enterobacter in malignant tumor patients [J]. Clinical Focus, 2020, 35(2): 166-169. |
[10] | Shi Youshan, Chen Tianhao. Pathogenic bacteria and etiological analysis of peritoneal dialysisassociated peritonitis in a single peritoneal dialysis center [J]. Clinical Focus, 2020, 35(11): 1010-1014. |
[11] | Liu Qimeng, Ye Huan. Risk factors for Carbapenemresistant and mortality in inpatients with pneumonia due to gramnegative bacteria [J]. Clinical Focus, 2019, 34(4): 334-338. |
[12] | Zhang Pan, Xie Shoujun, Wen Hainan. Distribution and drug resistance analysis of 1 113 strains of bloodstream infection [J]. Clinical Focus, 2019, 34(2): 148-153. |
[13] | Feng Sanli1,2, Zhang Jingnan2, Qiao Shukai2, Wang Wenfei1, Li Yang2, Xing Lina2, Guo Xiaonan2. Primary myelofibrosis with paroxysmal nocturnal hemoglobinuria: a case report and literature review [J]. Clinical Focus, 2019, 34(12): 1119-1122. |
[14] | Fan Xin1, Chen Xinfei2, Xiao Meng2, Xu Yingchun2. Research development on drug resistance and mechanisms of Clostridium difficile [J]. Clinical Focus, 2018, 33(5): 377-380. |
[15] | Gao Yan1, Li Linqian2, Wang Qian2, Zhang Si2, Zhang Haisong1. Hepatokines in pathogenesis of diabetic nephropathy [J]. Clinical Focus, 2018, 33(10): 859-862. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||